Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 1;8:46-60.

ALK Inhibitors for Clinical Use in Cancer Therapy

Affiliations
  • PMID: 26709645

ALK Inhibitors for Clinical Use in Cancer Therapy

Francesca Farina et al. Front Biosci (Elite Ed). .

Abstract

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase protein implicated in a variety of tumors, both solid and hematological. Few years ago crizotinib, an inhibitor of the receptor tyrosine kinases c-Met and ALK, demonstrated its activity in ALK positive non-small-cell lung cancer and other tumors with excellent toxicity profile. Subsequently several ALK inhibitors have been developed, offering new personalized treatment options. This review addresses some clinical considerations on the use of ALK inhibitors in ALK positive tumors and on the development of resistance to them.

Similar articles

See all similar articles

MeSH terms

Substances

Feedback